# Table of Contents

1. Introduction ................................................................. 4  
   1.1. Background ............................................................ 4  
   1.2. Practice Model ....................................................... 4  
   1.3. Programme Content ............................................... 4  
2. Programme Structure Overview ...................................... 5  
   2.1. Teaching Sessions .................................................. 5  
   2.2. Clinical Practicum ................................................ 5  
   2.3. Assessment .......................................................... 5  
3. Teaching Sessions ....................................................... 6  
   3.1. General .............................................................. 6  
   3.2. Consultations and Physical Assessments ....................... 6  
   3.3 Pharmacotherapeutics ............................................... 6  
4. Clinical Practicum ....................................................... 7  
   4.1. Clinical Supervisor ................................................ 7  
   4.2. Instructions for Trainee ........................................... 7  
   4.3. Final Report ........................................................ 8  
5. Assessments .................................................................. 9  
   5.1. Prescribing Portfolio ................................................ 9  
      5.1.1. Scope of Practice ............................................... 9  
      5.1.2. Personal Drug Formulary ...................................... 9  
      5.1.3. Personal Development Plan .................................. 10  
      5.1.4. Drug Monograph and Clinical Application of Drug Use ............................................... 10  
      5.1.5. Learning Log .................................................... 11  
      5.1.6. Prescribing Log ................................................ 11  
      5.1.7. Mini Clinical Evaluation Exercise (Mini-CEX) ........ 12  
      5.1.8. Case-Based Discussion ...................................... 12  
   5.2. Formative OSCE ...................................................... 13  
   5.3. Final Written Exam .................................................. 13  
   5.4. Summative OSCE ..................................................... 13  
6. Successful Completion .................................................. 14  
   6.1. Attendance Requirement .......................................... 14  
   6.2. Schedule of Assessment .......................................... 14  
   6.3. Failure to Progress in Practice ................................... 15  
   6.4. Unsafe Practice ...................................................... 15
Annex A. Learning Outcomes............................................................................................................ 16
  A1. Consultation Competencies........................................................................................................ 16
  A2. Prescribing Competencies ........................................................................................................ 18
Annex B. List of Presenting Complaints / Conditions........................................................................ 20
Annex C. Portfolio Review Form ........................................................................................................ 22
Annex D. Drug Monograph Form ...................................................................................................... 23
Annex E. Presentation Assessment Rubrics......................................................................................... 24
Annex F. Mini-CEX Form .................................................................................................................... 25
Annex G. Case-Based Discussion (CBD) Form .................................................................................. 27
Annex H. Level of case complexity ..................................................................................................... 29
Annex I. Clinical Supervisor Final Report .......................................................................................... 30
Annex J. Overview of Programme Structure....................................................................................... 31
1. Introduction

1.1. Background

Healthcare provision, with increasing complexity and patient load, is progressively experiencing the benefits of inter-professional collaboration. Since the late 1990s, pharmacists have been involved in medication management and titration at anticoagulation clinics. Over the years, this practice evolved to various other pharmacist-managed clinics and services e.g. heart failure, renal, diabetes management. Advanced Practice Nurses (APNs) undergo the Masters of Nursing programme and were certified from mid 2000s. Since then, APNs have been practicing in various settings and disciplines, being heavily involved in patient care, including medication management.

To further improve care accessibility, and provide quality care without compromising patient safety, the Ministry of Health, Singapore is advocating selected APNs and pharmacists to become collaborative prescribing practitioners where their scope of practice will be expanded.

1.2. Practice Model

Collaborative prescribing aims to assist and facilitate care transformation in the community and hospitals, by providing a more holistic service with improved continuity for team-based care. The collaborative prescribing practitioner (CPP) is a member of a multidisciplinary clinical team led by a medical practitioner and his/her scope of practice is a set of services performed as part of a team. The scope and services are defined in a Collaborative Practice Agreement, under the governance of the institution, according to National standards and guidelines.

1.3. Programme Content

The National Collaborative Prescribing Programme prepares APNs and pharmacists to prescribe under a Collaborative Practice Agreement with a medical practitioner(s). Collaborative prescribing involves assessing the patient, considering treatment options, reaching a shared decision, prescribing, providing patient education, monitoring and reviewing of the patient. Through this programme, the individual will acquire skills and competencies in history taking, data interpretation, diagnostic formulation, physical examination, clinical decision making, applied therapeutics, psychosocial aspects of prescribing, collaboration with multidisciplinary team, effective communication and documentation.

The programme is designed to build on the basic skills already acquired in the APNs’ and pharmacists’ training. The core components comprise of areas involving safe and professional prescribing, as well as improving prescribing practice and prescribing as part of a team. The core competencies required include inter-professional collaboration, understanding prescribing systems, and professional and ethical considerations of prescribing. Based on differences in baseline skillsets of APNs and pharmacists, a portion of the curriculum is conducted separately to strengthen areas requiring further skills development in the two professions to perform collaborative prescribing.

At the end of the programme, the CPP should be able to develop his/her own practice under a Collaborative Practice Agreement. The CPP should also be aware of his/her own strengths and limitations, scope of practice and practice framework that he/she should practice within.
2. Programme Structure Overview

The three-month programme is conducted over 13 weeks, with one full day a week (Mondays) in teaching sessions over 9 weeks, and an additional 80 hours of clinical practicum.

2.1. Teaching Sessions

Teaching methods include lectures, case-based discussions, clinical stimulations, role-play, hands-on practice, problem/team based learning, as well as self-directed and e-learning.

2.2. Clinical Practicum

An existing or potential collaborative prescribing practice with a clinical supervisor is required for the programme. The clinical supervisor (together with his/her team) will oversee the clinical practicum to ensure opportunities for hands-on practice and the individual’s competency to practice independently as a CPP.

Please refer to the Clinical Practicum section for details.

2.3. Assessment

For successful completion of the CP Programme, the candidate must have achieved a minimum of 75% attendance, and successfully completed the following assessments:

- Portfolio reviews: please refer to Portfolio section for details
- Oral presentation
- In-class quizzes
- A final written examination, and
- A formative and a summative OSCE.
3. Teaching Sessions

3.1. General

Topics to be covered include legislative aspects and principles of prescribing (refer to CP website for more details).

3.2. Consultations and Physical Assessments

Topics to be covered include general approaches to patients, communication skills, history-taking and physical assessment sessions (refer to CP website for more details).

3.3 Pharmacotherapeutics

Topics to be covered include pharmacokinetics and pharmacodynamics, and pharmacotherapeutics of cardiovascular, respiratory, infectious, endocrine, renal, gastrointestinal, neurological, psychiatric disorder/diseases (refer to CP website for more details).
4. Clinical Practicum

The aim of the period of clinical practicum is to provide you with opportunities to develop competencies in consultation prescribing under the supervision of your clinical supervisor. The period will be spent with the patient group/s for which you hopefully will be expecting to manage and prescribe upon satisfactory completion of the programme.

4.1. Clinical Supervisor

The following are key criteria in determining the suitability of a doctor to take on the role of clinical supervisor who will provide supervision, support and opportunities to develop your competence in prescribing practice:

The doctor must be a registered medical practitioner who:

- Has been nominated by the Head of Department / Service (HOD),
- Has at least 3 years of recent clinical experience in the field of practice related to your field / scope of practice, and
- Has some training and experience in teaching and/or supervising in practice, and preferably acknowledged by HOD and/or peers as a good teacher/supervisor.

A principal consideration is the willingness, availability and skills of the doctor to supervise and facilitate your learning during the Clinical Practicum. You as an active learner together with the HOD should discuss and therefore identify the most suitable doctor to be nominated as the clinical supervisor.

4.2. Instructions for Trainee

At the beginning of the programme, you are required to develop a personal development plan for the 10 weeks of clinical practicum. This is designed to help direct what you need to achieve in your clinical practicum. Examples of how previous trainees have spent this time include:

- observing how the medical practitioner conducts a ‘consultation/interview’ with patients and/or their carer’s and the development of a subsequent management plan;
- in-depth discussion and analysis of clinical management between them self and the clinical supervisor, using a random case analysis approach, when patient care and prescribing behaviour can be examined further;
- the clinical supervisor encouraging critical thinking and reflection with the use of the prescribing portfolio;
- trainees being observed carrying out consultations and suggesting clinical management and prescribing options which are then discussed with the medical practitioner;
- the clinical supervisor observing the trainee’s abilities to consult and communicate, physically examine and monitor, and prescribe both within and outside of a clinical management plan.

You are required to secure and document a minimum of 80 hours clinical supervision, which involves the following breakdown of hours:

- 30 hours DIRECT supervision:
  - 12 hours with named clinical supervisor
  - 18 hours with Senior Resident and above
- 10 hours INDIRECT supervision by above
• 30 hours DIRECT supervision by peers i.e. Resident/Medical Officer, APN or pharmacist
• 10 hours INDIRECT supervision by peers

Whereby

➢ DIRECT supervision means that the supervisor must be in attendance in the same room as the trainee to observe the trainee’s clinical encounter / performance, and provide feedback;
➢ INDIRECT supervision means that the supervisor is physically present on the premises (but not in the same room) when the trainee is engaged in the clinical encounter / performing the task, and is available at the trainee’s side within a few minutes if help is needed.

The duration of each session of the clinical practicum should be decided between you and your clinical supervisor, and the other supervisors i.e. peers (APNs or pharmacists), senior residents and other doctors etc.

For each period of time that you spend under the supervision of your clinical supervisor, you must complete a learning log that needs to be verified with your clinical supervisor’s signature (see section 5.1.5 Learning log).

During the clinical practicum, you must also complete at least two mini-clinical evaluation exercises (mini-CEXs) and two case-based discussions (CBDs) assessment. Please see the relevant sections for details.

4.3. Final Report

At the end of the clinical practicum, you will give your clinical supervisor a copy of this form (refer to Annex I) to complete for the final signing-off process.
5. Assessments

5.1. Prescribing Portfolio

There are a number of sections to the portfolio. They include:

- Identifying your scope of practice (refer to section 5.1.1) and personal drug formulary (refer to section 5.1.2);
- Developing a personal development plan (refer to section 5.1.3);
- Presenting a drug monograph and clinical application use (refer to section 5.1.4) which must be related to your scope of practice and personal drug formulary;
- Details of your supervised time in practice in a learning log (refer to section 5.1.5);
- Providing evidence that the prescribing practice outcomes are completed and signed off in prescribing logs (refer to section 5.1.6);
- Developing patient assessment skills using mini-CEXs (refer to section 5.1.7) and case-based discussions (refer to section 5.1.8);
- A statement from the clinical supervisor that your patient assessment skills are developed sufficiently and that they are satisfied that you will be a Collaborative Prescribing Practitioner.

You must attain successful completion of the portfolio in order to qualify for entry into the OSCE (Objective Structured Clinical Examination). Failure to complete the portfolio automatically disqualifies you from attempting the OSCE.

A portfolio review form (refer to Annex C) will be used for the various peer portfolio review and final submission of portfolio. Each section that needs to be reviewed will be listed in the form, with additional rows to list any additional work done, or section(s) not completed in previous portfolio review. Please refer to CP website for the latest form.

5.1.1. Scope of Practice

It is vitally important that you discuss and agree your scope of practice and identified learning needs with your clinical supervisor so that they can be developed as part of your time in practice. Your clinical supervisor should sign your scope of practice document.

Your scope of practice, in line with the Collaborative Prescribing Competency Framework, should include the following:

- Medical conditions and/or defined patient groups.
- Drug Formulary (excluding unregistered Therapeutic Products and clinical trial drugs).
- Clinical Decisions, which refers to assessment and treatment based on guideline, protocol or treatment algorithm.
- Tests and Investigations.
- Escalation Criteria.
- Patient Exclusion (or inclusion) Criteria.

5.1.2. Personal Drug Formulary

Information recommended for your personal formulary includes the following:

- Drug class / Disease (to allow grouping of the drugs)
- Drug name
- Remarks to be used at your discretion
5.1.3. Personal Development Plan

To ensure that you are able to utilise your time more effectively, you are encouraged to identify your development needs. This may be done by assessing yourself against the identified programme’s learning outcomes, which is related to the CP competency framework. Priority should be given to those outcomes/areas that you have identified to require improvement or in need of development.

Include the following details in your development plan:

- How will this outcome be achieved?
- How do you know if it has been achieved?
- What is the date for planned completion?
- What support is required to ensure it is achieved and where will the support come from?
- What are the potential barriers and how can they be overcome?

Before submitting the portfolio, you are encouraged to have one final review of the form and, at the same time, update and develop a new personal development plan that you can take into the first year of being a prescriber.

5.1.4. Drug Monograph and Clinical Application of Drug Use

This section is designed for you to familiarise yourself with a number of drugs that you will be prescribing.

Choose a drug from your personal drug formulary and gather the following information:

- Indication and dosing
- Strength and dosage forms
- Drug class
- Mechanism of action
- Pharmacokinetics
- Contraindications
- Precautions
- Administration considerations
- Monitoring parameters
- Common and clinically relevant side effects
- Common and clinically relevant drug / diet interactions

Using patient/s example, illustrate the application of this drug to clinical practice, including the following information:

- List the indications in your patient
- Summarise the evidence for its use
  - If there are alternative drugs for your patient’s problem/diagnosis, list the reason(s) you chose this drug instead of alternatives
- Describe how the pharmacokinetics affect your patient
  - If a special group of patients is affected by this drug, state the characteristics of this group of patients and how the drug / pharmacokinetics affect them
- Describe the reasons for these contraindications
- Describe the reasons for these precautions
  - Describe what you will do if precautions apply to your patient but he/she needs this drug
• List the administration considerations for your patient:
• Describe your monitoring plan
• Describe how you communicate these side effects to your patient
  - Describe the advice that you gave on what to do if these side effects occur
• Describe how you communicate these drug/diet interactions to your patient
  - Describe the advice that you gave on what to do if these drug/diet interactions occur

The drug monograph form (refer to Annex D) should be completed using Calibri, minimal font size 10, single line spacing and on 2 pages only.

The completion and submission of the drug monograph form is accompanied by a 10-minute presentation to peers (refer to Annex E for presentation assessment rubrics).

5.1.5. Learning Log

You must attend a minimum of 80 hours of supervised and educationally – led practice i.e. clinical practicum, and this must be dated and signed by your clinical supervisor and/or supervising peers.

For each session you must state:
• Date and number of hours
• Brief description of cases seen (eg. Medication counselling session)
• Key learning points from session, relating to key prescribing competencies
• Cumulative total hours (to be signed by your clinical supervisor before each portfolio review)

*Failure to document the required number of hours will result in a fail being awarded.*

This can be a WORD document or if easier you can construct a table.

5.1.6. Prescribing Log

Unlike a learning log, where you record all sessions supervised in brief (1-2 lines), the prescribing logs provide detailed information on cases encountered with an emphasis on pharmacological management. You are required to complete only 5 prescribing logs.

• The first log is related to therapeutics and different aspects of decision making in prescribing.
• The second log should focus on pharmacokinetics interaction and/or dose adjustment such as therapeutic drug monitoring, dose adjustment in renal/hepatic impairment, age-related dose adjustment.

This is the suggested layout of the prescribing logs:
• **Case Summary**, which should include history of present illness, examinations, clinical findings, medications and allergies
• **Diagnosis**, which should include differential diagnosis
• **Pharmacological Treatment / Therapeutic Target(s)/Goal(s)**, which should include drug name, dosage form, dose, frequency and total amount
• **Counselling, Monitoring**, which should include pharmacotherapy and non-pharmacotherapy advice; monitoring for efficacy or adverse effects
• **Referral/Review**, to be included if referral to another healthcare professional is necessary
• **Learning Points**, which should include Guidelines or References used.
5.1.7. Mini Clinical Evaluation Exercise (Mini-CEX)

A major element of safe and effective prescribing is the ability to undertake an effective consultation. The consultation may include physical examination, history taking, interpersonal skills, problem-solving skills, decision making and development of a treatment plan.

The mini-CEX is designed to assess your ability to undertake a consultation in your own area of practice. It is assessed by your clinical supervisor and/or supervising peer.

A mini-CEX form (refer to Annex F) must be used to ensure that all trainees are assessed against the same criteria. Please make sure that all information is anonymised and no patient identifiable information is mentioned in the mini-CEX.

The assessment comprises of the following category:

- History-taking
- Physical examination
- Clinical judgement and reasoning
- Organization and efficiency
- Counselling and communication skills
- Consideration for patient / professionalism
- Global impression scale

For each consultation used, you should include a short description of 3 to 5 lines introducing the case.

Your clinical supervisor and/or supervising peers are required to provide comments on areas of strength, and suggestions for development in the form, and you should discuss and note down agreed learning goals for next assessment.

5.1.8. Case-Based Discussion

The case-based discussion is used to assess clinical decision-making and the application or use of medical and pharmacotherapy knowledge with actual patients. Your clinical supervisor will question you about the care provided probing for reasons behind the work-up, diagnoses, interpretation of clinical findings, and treatment plans.

Cases suitable for case-based discussion are (1) inpatients who have been treated and discharged so that all the clinical information is available or (2) outpatients whose acute problems have been treated and/or chronic illnesses are at a steady state. Please make sure that all information discussed is anonymised and no patient identifiable information is mentioned in the discussion.

This list of questions is suggested for your clinical supervisor’s case-based discussion with you, which he/she is at liberty to use some or all:

- What are the key findings from the history? Are there any red flags?
- What are the key findings from the physical examination? Are there any red flags?
- What are your differential diagnoses or issues identified for this patients? How did you arrive at your diagnosis(es)?
- What are the investigations you would consider? Why?
- What are the treatment options available to this patient? Why?
- Are there any specific considerations concerning the prescription of treatment for this patient?
- Does this patient need to be referred to another practitioner for further management?
• What are the follow-up / monitoring considerations?

A case-based discussion form (refer to Annex G) must be used to ensure that all trainees are assessed against the same criteria.

The assessment comprises of the following category:

• Data collection and presentation
• Synthesis and analysis of health information
• Clinical reasoning and approach to diagnostic studies
• Management and therapeutic plans
• Use of Evidence-Based Medicine
• Global impression

Similar to the mini-CEX, for each consultation used, the trainee should submit a short description of 3 to 5 lines introducing the case.

Your clinical supervisor and/or supervising peers are required to provide comments on areas of strength, and suggestions for development in the form, and you should discuss and note down agreed learning goals for next assessment.

5.2. Formative OSCE

More details will be provided at a later date.

5.3. Final Written Exam

The 2-hour closed book written examination consists of 60 multiple choice questions (MCQs).

5.4. Summative OSCE

More details will be provided at a later date.
6. Successful Completion

6.1. Attendance Requirement

All trainees must meet minimum attendance of 75% (i.e. 6 out of 8 teaching sessions) to be eligible to enter for OSCE and graduation.

6.2. Schedule of Assessment

All trainees must undertake and complete all aspects of assessments. There are no arrangements for compensations between assessments. The decision tree with respect to written examination and summative OSCE is presented in the diagram below.

The written exam and the summative OSCE are non-compensatory i.e. the candidate must pass both components to graduate. The 2 components are independent i.e. the candidate can attempt and re-attempt the written exam and OSCE regardless of performance in the other component, till the maximum number of attempts or maximum candidature is reached.
In essence:

- The maximum duration of candidature is 2 years from the start to successful completion of the programme inclusive of interruption of study and approved leave of absence.
- The candidate who completes the programme successfully will be presented with a Certificate of Successful Completion.
- Successful completion is defined as:
  - Meets minimum attendance to enter for OSCE, and
  - Completes all portfolio requirements to enter for OSCE, and
  - Attains a pass for written examination, and
  - Attains a pass for summative OSCE.
- Attendance at the formative OSCE is mandatory.
- Each candidate is allowed 4 attempts at the written examination and 3 attempts at the summative OSCE, all of which must be within the 2-year candidature period.
- If the candidate fails his/her 3rd attempt at the written examination AND/OR 2nd attempt at the summative OSCE, he/she must re-attend the entire programme i.e. re-course before he/she is allowed to make a final attempt at the written examination and/or summative OSCE. All attempts must be within the 2-year candidature period.

6.3. Failure to Progress in Practice

Where there is concern that a trainee is failing to achieve a satisfactory standard in practice, the clinical supervisor MUST contact the programme manager. A visit to the placement area will be arranged to undertake joint discussions between the trainee, supervisor and programme manager or designee. This will be documented. A joint documented plan of action will be developed to facilitate the trainee’s remediation and progress before the final competency grade in relation to the practice outcomes is given. It is important that there is documentation of issues raised, follow up actions and progress meetings as the evidence may be required to be presented to the examination board.

6.4. Unsafe Practice

The institution patient and clinical safety protocols and requirements will apply to you during the clinical practicum. If your clinical supervisor have any concern about you in this aspect your clinical supervisor is encouraged to intervene early so that you have sufficient time to remediate and improve your practice.
Annex A. Learning Outcomes

A1. Consultation Competencies

On completion of the programme, the student should be able to perform the following key tasks:

1. **Assess Patient**
   1.1. Accesses, consolidates and interprets all available and relevant patient records.
   1.2. Interviews patient/caregiver to obtain an appropriate clinical, psychosocial and medication history including over the counter/ traditional medicines, online medicines and drug allergies.
   1.3. Performs relevant physical examinations, where appropriate.
   1.4. Requests and interprets relevant investigations necessary to inform treatment options.
   1.5. Makes, confirms and documents the working or final diagnosis by systematically considering the various possibilities (differential diagnosis).
   1.6. Knows the condition(s) being treated and their natural progression.
   1.7. Assesses their severity, deterioration and anticipated response to treatment.
   1.8. Reviews adherence to and safety and efficacy of current treatment plan.
   1.9. Collaborates and consults with another member of the team, a specialist or a prescribing information source when necessary.

2. **Consider treatment option**
   2.1. Knows non-pharmacological and pharmacological treatment options.
   2.2. Chooses the most appropriate medication based on safety, efficacy and cost effectiveness and prescribes doses adjusted according to disease and clinical conditions, including dose optimisation.
   2.3. Stops treatment (de-prescribing), if there is no indication.
   2.4. Assesses the risks and benefits to the patient of taking or not taking a medicine or treatment.
   2.5. Knows and applies understanding of the pharmacodynamics and pharmacokinetics of medication being prescribed and how these may be altered (e.g. by genetics, age, renal impairment, pregnancy).
   2.6. Assesses how co-morbidities, existing medication, allergies, contraindications and quality of life impact on management options.
   2.7. Takes into account psychosocial aspects of patient (e.g. ability to swallow, religion, affordability) and the potential impact on route of administration and formulation of medicines.
   2.8. Identifies, accesses, and uses reliable and validated sources of information and critically evaluates other information.
   2.9. Knows and stays up-to-date in own area of practice and apply the principles of evidence-based practice, including clinical and cost-effectiveness.
   2.10. Takes into account the wider perspective including the public health issues related to medicines and their use and promoting health.
   2.11. Knows antimicrobial resistance and the roles of infection prevention, control and antimicrobial stewardship measures.

3. **Reach a shared decision (with patient/caregiver)**
   3.1. Builds rapport with patient and/or caregivers.
   3.2. Identifies and respects the patient and/or caregivers in relation to diversity in values, beliefs and expectations about their health and treatment with medicines.
   3.3. Explains the rationale behind and the potential risks and benefits of management options in a way the patient and/or caregiver understands, including discontinuing treatment.
3.4. Works with the patient and/or caregiver in partnership to make informed choices, agreeing on a treatment plan that respects patient preferences including their right to refuse or limit treatment.

3.5. Assesses adherence in a non-judgmental way and understands the different reasons for non-adherence (intentional or non-intentional) and how best to support patients/caregivers.

3.6. Explores the patient/caregivers understanding and expectations of a consultation and aims for a satisfactory outcome for the patient/caregiver and prescriber.

3.7. Develops, finalises, implements and documents the treatment plan.

4. **Prescribe**

4.1. Prescribes a medicine safely with knowledge of its mechanism of action, indications, dose, contraindications, interactions and adverse effects.

4.2. Knows the potential for adverse effects and takes steps to avoid/minimise, monitor and manage them.

4.3. Ensures no omission of medicine resulting from any untreated indication.

4.4. Ensures medicines without indications are discontinued.

4.5. Prescribes within relevant frameworks for medicines use as appropriate (e.g. local formularies, care pathways, protocols and guidelines).

4.6. Prescribes generic medicines for cost effectiveness and when medicines with narrow therapeutic index should be prescribed by specific brands.

4.7. Knows relevant national frameworks for medicines use and ability to apply them to own prescribing practice.

4.8. Completes accurately and checks calculations relevant to prescribing and practical dosing routinely.

4.9. Considers the potential for misuse of medicines.

4.10. Uses up-to-date information about prescribed medicines (e.g. availability, pack sizes, storage conditions, excipients, costs).

4.11. Generates electronically or writes legible unambiguous and complete prescriptions which meet legal requirements.

4.12. Uses effectively the systems necessary to prescribe medicines (e.g. medicine charts, electronic prescribing, decision support).


4.14. Communicates information about medicines and what they are being used for when sharing or transferring prescribing responsibilities / information.

5. **Provide patient education**

5.1. Establishes the patient/caregiver’s understanding of and commitment to the patient’s clinical management, monitoring and follow-up.

5.2. Gives the patient/caregiver clear, understandable and accessible medication information (e.g. what it is for, how to use it, possible unwanted effects and how to manage and/or report them, expected duration of treatment).

5.3. Guides patients/caregivers on how to identify reliable sources of information about their medicines and treatments.

5.4. Ensures that the patient/caregiver knows what to do if there are any concerns about the management of their condition, if the condition deteriorates or if there is no improvement in a specific time frame.

5.5. Encourages and supports patients/caregivers when possible, to take responsibility for their medicines and self-manage their conditions.
6. **Monitor and review**

6.2. Ensures that the effectiveness of treatment and potential unwanted effects are monitored.
6.3. Detects and reports suspected adverse drug reactions using appropriate reporting systems.
6.4. Reviews and adjusts the management plan in response to patient’s clinical progress and patient’s preferences.
6.5. Recommends an appropriate duration for next monitoring and review.

**A2. Prescribing Competencies**

On completion of the programme, the student should be able to perform the following key tasks:

1. **Prescribe safely**
   1.1 Prescribes within own scope of practice and recognises the limits of own knowledge and skill
   1.2 Knows common types and causes of medication errors and how to prevent, avoid and detect them
   1.3 Identifies the potential risks associated with prescribing via remote media (telephone, email or through a third party) and takes steps to minimise them
   1.4 Minimises risks to patients by using or developing processes that support safe prescribing particularly in areas of high risk (e.g. transfer of information about medicines, prescribing of repeat medicines)
   1.5 Keeps up to date with emerging safety concerns related to prescribing
   1.6 Reports prescribing errors, near misses and critical incidents, and reviews practice to prevent recurrence

2. **Prescribe professionally**
   2.1 Ensures confidence and competence to prescribe are maintained.
   2.2 Accepts personal responsibility for prescribing and understands the legal and ethical implications.
   2.3 Works within legal and regulatory frameworks affecting prescribing practice (e.g. controlled drugs, prescribing of unlicensed/off label medicines, regulators guidance, supplementary prescribing).
   2.4 Makes prescribing decisions based on the needs of patients and not the prescriber’s personal considerations.
   2.5 Recognises and deals with factors that might unduly influence prescribing (e.g. pharmaceutical industry, media, patient, colleagues).

3. **Improve prescribing practice**
   3.1 Reflects on own and others’ prescribing practice, and acts upon feedback and discussion.
   3.2 Act upon (whistle blow) colleagues’ inappropriate or unsafe prescribing practice using appropriate mechanisms.
   3.3 Knows the available tools and use them to improve prescribing (e.g. patient and peer review feedback, prescribing data analysis and audit).
4. **Prescribe as part of a team**

4.1 Acts as part of a multidisciplinary team to ensure that continuity of care across care settings is developed and not compromised.

4.2 Establishes rapport with other professionals based on understanding, trust and respect for each other’s roles in relation to prescribing.

4.3 Negotiates the appropriate level of support and supervision for role as a prescriber.

4.4 Provides support and advice to other prescribers or those involved in administration of medicines where appropriate.
# Annex B. List of Presenting Complaints / Conditions

<table>
<thead>
<tr>
<th>System</th>
<th>Conditions</th>
<th>Presenting Complaints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>• Hypertension</td>
<td>• Chest pain</td>
</tr>
<tr>
<td></td>
<td>• Hyperlipidaemia</td>
<td>• Palpitation</td>
</tr>
<tr>
<td></td>
<td>• Common arrhythmias</td>
<td>• Syncope</td>
</tr>
<tr>
<td></td>
<td>• Heart failure</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Myocardial infarction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Venous thromboembolism (VTE)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Peripheral vascular disease (PAD)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Chest pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Palpitation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Syncope</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Shortness of breath</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Cough</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Haemoptysis</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>• Chronic obstructive pulmonary disease (COPD)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Asthma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Pneumonia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Bronchitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Upper respiratory tract infection (URTI)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tuberculosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Polydipsia, thirst</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Leg pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Weight loss</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Neck mass</td>
<td></td>
</tr>
<tr>
<td>Endocrine</td>
<td>• Diabetes mellitus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Leg ulcers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Hypothyroidism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Hyperthyroidism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Polydipsia, thirst</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Leg pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Weight loss</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Neck mass</td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>• Renal failure</td>
<td>• Abnormal renal function</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>• Peptic ulcer disease (PUD)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Gastritis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Gastroesophageal reflux disease (GERD)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Hepatitis A</td>
<td>• Abdominal pain and masses</td>
</tr>
<tr>
<td></td>
<td>• Hepatitis B</td>
<td>• Bleeding gastrointestinal tract</td>
</tr>
<tr>
<td></td>
<td>• Hepatitis C</td>
<td>• Diarrhoea</td>
</tr>
<tr>
<td></td>
<td>• Abdominal pain and masses</td>
<td>• Nausea and vomiting</td>
</tr>
<tr>
<td></td>
<td>• Bleeding gastrointestinal tract</td>
<td>• Change in bowel habit</td>
</tr>
<tr>
<td></td>
<td>• Diarrhoea</td>
<td>• Abnormal liver function test</td>
</tr>
<tr>
<td></td>
<td>• Nausea and vomiting</td>
<td>• Jaundice</td>
</tr>
<tr>
<td>Neurology</td>
<td>• Dementia</td>
<td>• Extrapyramidal side effects</td>
</tr>
<tr>
<td></td>
<td>• Stroke (FAST)</td>
<td>• Altered mental state</td>
</tr>
<tr>
<td></td>
<td>• Epilepsy</td>
<td>• Delirium</td>
</tr>
<tr>
<td></td>
<td>• Extrapyramidal side effects</td>
<td>• Weakness</td>
</tr>
<tr>
<td></td>
<td>• Altered mental state</td>
<td>• Headache</td>
</tr>
<tr>
<td></td>
<td>• Delirium</td>
<td>• Lack of energy</td>
</tr>
<tr>
<td>Psychiatry</td>
<td>• Depression</td>
<td>• Low mood</td>
</tr>
<tr>
<td></td>
<td>• Anxiety</td>
<td>• Lack of energy</td>
</tr>
<tr>
<td></td>
<td>• Stress</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Insomnia</td>
<td></td>
</tr>
<tr>
<td>System</td>
<td>Conditions</td>
<td>Presenting Complaints</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------------------------------------</td>
<td>-----------------------------------------------------</td>
</tr>
</tbody>
</table>
| Musculoskeletal                | • Osteoarthritis  
• Osteoporosis  
• Sport and soft tissue injuries  
• Joint pain  
• Back pain with/without radiculopathy |
| Others (infectious diseases)   | • Lower urinary tract infection  
• Cystitis  
• Conjunctivitis  
• Chicken pox  
• Herpes zoster  
• Dysuria  
• Hematuria  
• Red eyes, itchy eyes  
• Eye crusting  
• Vesicular rash  
• Nerve pain  
• Fever  
• Leg swelling  
• Functional decline  
• Loss of appetite |
| General                        | • Anemia                                        |                                                     |
# Annex C. Portfolio Review Form

Trainee’s name: ……………………………………………..   Institution: ……………………………………………..

<table>
<thead>
<tr>
<th>Item</th>
<th>Has this item been completed?*</th>
<th>Remarks / Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scope Of Practice</td>
<td>☐ Yes ☐ No</td>
<td></td>
</tr>
<tr>
<td>Personal Drug Formulary</td>
<td>☐ Yes ☐ No</td>
<td></td>
</tr>
<tr>
<td>Personal Development Plan</td>
<td>☐ Yes ☐ No</td>
<td></td>
</tr>
<tr>
<td>Drug Monograph Presentation</td>
<td>☐ Yes ☐ No</td>
<td></td>
</tr>
<tr>
<td>Learning Log</td>
<td>☐ Yes ☐ No</td>
<td></td>
</tr>
<tr>
<td>Prescribing Log 1</td>
<td>☐ Yes ☐ No</td>
<td></td>
</tr>
</tbody>
</table>

*If the item is not completed please provide an explanation

This portfolio has been reviewed on _____________ (date) by the following peers:

- Name: ________________________________   Signature: _______________________
- Name: ________________________________   Signature: _______________________
- Name: ________________________________   Signature: _______________________
- Name: ________________________________   Signature: _______________________
- Name: ________________________________   Signature: _______________________
- Name: ________________________________   Signature: _______________________
- Name: ________________________________   Signature: _______________________
- Name: ________________________________   Signature: _______________________
- Name: ________________________________   Signature: _______________________


Annex D. Drug Monograph Form

- The completion and submission of this form is accompanied by a 10-minute presentation to peers in the CP Programme at week 3
- Please include at least one patient example to illustrate the use of this drug in practice
- This form should be completed using Calibri, minimal font size 10, single line spacing and on 2 pages only

<table>
<thead>
<tr>
<th>Information gathered</th>
<th>Application to clinical practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Indication and dosing:</td>
<td>List the indications in your patient:</td>
</tr>
<tr>
<td>Strength and dosage forms:</td>
<td>Summarise the evidence for its use:</td>
</tr>
<tr>
<td></td>
<td>If there are alternative drugs for your patient’s problem/diagnosis, list the reason(s) you chose this drug instead of alternatives:</td>
</tr>
<tr>
<td>2. Drug class:</td>
<td>Describe how the pharmacokinetics affect your patient:</td>
</tr>
<tr>
<td>Mechanism of action:</td>
<td>If a special group of patients is affected by this drug, state the characteristics of this group of patients and how the drug / pharmacokinetics affect them:</td>
</tr>
<tr>
<td>Pharmacokinetics:</td>
<td></td>
</tr>
<tr>
<td>- Onset:</td>
<td></td>
</tr>
<tr>
<td>- Duration:</td>
<td></td>
</tr>
<tr>
<td>- Absorption:</td>
<td></td>
</tr>
<tr>
<td>- Distribution:</td>
<td></td>
</tr>
<tr>
<td>- Metabolism:</td>
<td></td>
</tr>
<tr>
<td>- Half-life elimination:</td>
<td></td>
</tr>
<tr>
<td>3. Contraindications:</td>
<td>Describe the reasons for these contraindications:</td>
</tr>
<tr>
<td>Precautions:</td>
<td>Describe the reasons for these precautions:</td>
</tr>
<tr>
<td></td>
<td>Describe what you will do if precautions apply to your patient but he/she needs this drug:</td>
</tr>
<tr>
<td>4. Administration considerations:</td>
<td>List the administration considerations for your patient:</td>
</tr>
<tr>
<td>Monitoring parameters:</td>
<td>Describe your monitoring plan:</td>
</tr>
<tr>
<td>5. Common and clinically relevant side effects:</td>
<td>Describe how you communicate these side effects to your patient:</td>
</tr>
<tr>
<td></td>
<td>Describe the advice that you gave on what to do if these side effects occur:</td>
</tr>
<tr>
<td>6. Common and clinically relevant drug / diet interactions</td>
<td>Describe how you communicate these drug / diet interactions to your patient:</td>
</tr>
<tr>
<td></td>
<td>Describe the advice that you gave on what to do if these drug / diet interactions occur:</td>
</tr>
</tbody>
</table>
## Annex E. Presentation Assessment Rubrics

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Needs improvement (NI)</th>
<th>Meets expectation (ME)</th>
<th>Exceeds expectation (EE)</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Content and information</td>
<td>Either insufficient or excessive; literature review is inadequate or excessive; assessor is unable to decipher important points either because there is insufficient or too much information</td>
<td>Adequate; literature review is adequate; assessor understands important points because the amount of information is just right</td>
<td>Appropriately in-depth; literature review is high-yield for learners; assessor understands important points and nuances in differentiation, safety etc.</td>
<td>Grade</td>
</tr>
<tr>
<td>Knowledge and understanding [1]</td>
<td>Facts[2] and concepts[2] are presented without clarification of inter-relationships; assessor is unable to discern the links between facts and concepts</td>
<td>Facts, concepts and inter-relationships are presented; assessor discerns the links between facts and concepts</td>
<td>Facts, concepts and inter-relationships are prioritised in the presentation; assessor discerns the links between facts and concepts, and their relative importance</td>
<td>Grade</td>
</tr>
<tr>
<td>Contextualisation and application</td>
<td>Applies use of the drug with some difficulty; unable to individualise therapy for specific patient groups; analysis and/or application thought processes have some ambiguities or gaps</td>
<td>Applies use of the drug to specific patient groups; explains the unique characteristics of the drug with respect to the patient groups; analysis and/or application thought processes are clear and logical</td>
<td>Applies use of the drug to specific patient and population groups; explains the unique characteristics of the drug and its impact on community and/or population; analysis and/or application thought processes are clear, logical and inspires learners to emulate</td>
<td>Grade</td>
</tr>
<tr>
<td>Presentation style and management of Q&amp;A</td>
<td>Disorganised; poor use of AV aid; does not listen actively and/or comprehend questions; does not respond in a way that facilitates understanding</td>
<td>Organised; good use of AV aid; listens actively to questions; response facilitates understanding and learning</td>
<td>Organised and stylish; expert use of AV aid; listens actively and probes effectively; response triggers learners to explore the subject further</td>
<td>Grade</td>
</tr>
<tr>
<td>Overall</td>
<td>Presentation has omissions and/or inaccuracies of concern. Often formulaic in approach and unable to contextualise to patient care. Struggled with the presentation or appeared disorganised and unpractised. Presenter is unfamiliar with the drug</td>
<td>Presentation is of a satisfactory standard with minimal or no omissions / errors. May be formulaic in approach at times e.g. not quite contextualised to patient care. Presentation is organised and adequately engaging. Presenter is familiar with the drug.</td>
<td>Presentation is of a high standard without any omissions / errors. Approach is that of a content expert. Presentation is completed confidently and fluently. Presenter has deep knowledge of the drug.</td>
<td>Grade</td>
</tr>
</tbody>
</table>


[2] Fact = specific and unique data or instance; Concept = a class of items, words, or ideas that are known by a common name, includes multiple specific examples, shares common features.
Annex F. Mini-CEX Form

Trainee’s name: …………………………………………… Assessor’s name: ……………………………………………

Focus:  □ Data gathering  □ Diagnosis  □ Counselling  □ Therapy / management

Complexity of case (see below):  □ Low  □ Medium  □ High

Presenting complaint: ___________________________ Date of clinical encounter: ________

Brief description of case:
_________________________________________________________________________________
_________________________________________________________________________________
_________________________________________________________________________________
_________________________________________________________________________________

Assessor: please grade the following items

<table>
<thead>
<tr>
<th>Assessor: please grade the following items</th>
<th>Needs Improvement</th>
<th>Meets Expectation</th>
<th>Exceeds Expectation</th>
<th>Not observed</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 History Taking</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Physical Examination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Clinical Judgment and Reasoning</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Organization and Efficiency</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Meets expectations: Facilitates patient’s telling of story; demonstrates effective use of questions to obtain accurate, adequate information (including medication history where appropriate) needed. Responds appropriately to affect and non-verbal cues.

Meets expectations: Follows an efficient logical sequence; balances screening/diagnostic steps for problem; informs patient; is sensitive to patient’s comfort and modesty.

Meets expectations: Generates an appropriate problem list/list of differential diagnoses; applies principles of evidence-based medicine in the selection of diagnostic studies, management and therapeutic plans with due consideration for patient’s clinical, financial and social-functional status and in context of team-based care; provides justification for choice of diagnostic studies, management and therapeutic plans; aims for comprehensive and holistic care.

Meets expectations: Prioritizes; is timely, succinct and paces patient without being brusque or abrupt; organizes interaction/workflow efficiently; is able to multi-task if required.
<table>
<thead>
<tr>
<th></th>
<th>Assessor: please grade the following items</th>
<th>Needs Improvement</th>
<th>Meets Expectation</th>
<th>Exceeds Expectation</th>
<th>Not observed</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Counselling and Communication Skills</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Meets expectations:* Explains rationale for treatment; facilitates shared decision-making; educates/counsels regarding management and provides appropriate oral/written information; checks patient’s understanding, compliance and need for more information.

| 6 | Consideration for patient / Professionalism |                   |                  |                   |              |

*Meets expectations:* Shows respect, compassion, empathy; establishes rapport; respects patient’s rights and choice; ensures confidentiality of information; interacts appropriately with peers, doctors, and other healthcare professionals; reflects appropriately on key lessons from current clinical encounter; draws up an appropriate action plan for improvement.

| 7 | Global Impression                          |                   |                  |                   |              |

*Meets expectations:* Completes the clinical encounter in a caring, effective and efficient manner; demonstrates sound judgment, reasoning and decision-making.

Areas of strength, areas for development (to be completed by assessor):

___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________

Agreed learning goals for next assessment (to be completed by student):

___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________

Trainee’s signature and date

.........................................................................................................................

Assessor’s signature and date

.........................................................................................................................
Annex G. Case-Based Discussion (CBD) Form

Trainee’s name: .................................................... Assessor’s name: ..........................................................

Instruction to Trainee and Assessor:

- Cases suitable for case-based discussion are (1) inpatients who have been treated and discharged so that all the clinical information is available or (2) outpatients whose acute problems have been treated and/or chronic illnesses are at a steady state.

Complexity of case (see below):  ☐ Low  ☐ Medium  ☐ High

Presenting complaint: ___________________________ Date of clinical encounter: __________

Brief description of case:

________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________

Assessor: please grade the following items

<table>
<thead>
<tr>
<th>Assessor: please grade the following items</th>
<th>Needs Improvement</th>
<th>Meets Expectation</th>
<th>Exceeds Expectation</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  Data Collection and Presentation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2  Synthesis and Analysis of Health Information</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3  Clinical Reasoning and Approach to Diagnostic Studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Meets expectations:

1. Collects and organizes relevant information including presenting complaint, history of present illness, medical, surgical and gynaecologic history if relevant, drug allergy and medication history (including adherence, adverse drug reactions etc.), social, family and occupational history, relevant physical assessment findings
2. Highlights any missing information, ambiguity or uncertainty and explains how that is managed
3. Presents the case succinctly with appropriate emphasis on key aspects

Meet expectations:

1. Analyses and interprets correctly information from history and physical assessment
2. Detects and interprets pertinent positives and pertinent negatives
3. Makes sense of the information and relates it to patient’s unique characteristics / circumstances

Meets expectations:

1. Formulates and prioritizes differential diagnoses / problem list with justifications
2. Selects and organizes appropriate diagnostic studies (including laboratory, imaging etc.) and considers risks, benefits
3. Interprets results of diagnostic studies with respect to differential diagnoses / problem list
<table>
<thead>
<tr>
<th>Assessor: please grade the following items</th>
<th>Needs Improvement</th>
<th>Meets Expectation</th>
<th>Exceeds Expectation</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Management and Therapeutic Plans</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

*Meets expectations:*

1. Proposes care that is contextualised to patient’s immediate and intermediate needs, and respectful of patient’s rights and choice
2. Specifies measurable/observable therapeutic goals that integrate multidisciplinary/interprofessional input
3. Explains the rationale for therapeutic goals and pharmacologic interventions
4. Interprets patient’s response and progress with respect to management plans including pharmacologic intervention
5. Reviews medication list and if applicable, interprets pharmacologic / drug therapy problems e.g. indications, effectiveness, appropriateness of drug, dose, dosage form, regime, monitoring or adherence, contraindications, adverse drug reactions or drug/food interactions
6. Explains rationale for monitoring plans and if applicable, adjustment to plans

| 5 Use of Evidence Based Medicine | ☐ | ☐ | ☐ | ☐ |

*Meets expectations:*

1. Describes evidence that supports the diagnostic studies, management and therapeutic plans
2. Where an alternative is selected, explains the rationale for the decision

| 6 Global Impression | ☐ | ☐ | ☐ | ☐ |

*Meets Expectation:*

1. Analyses and discusses the case with an appropriate level of reasoning, judgment and decision-making
2. Discusses the case in a manner that is respectful of patients and colleagues

Areas of strength; areas for development (to be completed by assessor):

______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

Agreed learning goals for next assessment (to be completed by student):

______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

Trainee’s signature and date

Assessor’s signature and date
## Annex H. Level of case complexity

Complexity of case in Mini-CEX and case-based discussion is described as:

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
</table>
| Low   | A patient with single-system presentation with minimal complications (medical and/or social) and responsive to first-line treatment  
|       | A patient with a self-evident diagnosis where management is straightforward.  
|       | A stable patient, with a common presentation or a clear diagnosis. |
| Medium| A patient with multi-system problem and minimal complications (medical or/and social).  
|       | A patient with a single-system problem, and multiple/significant complication (medical and/or social) or who does not respond to first line treatment.  
|       | A stable patient with an uncommon presentation or without a clear diagnosis.  
|       | A critically-ill or injured patient who responds to first line treatment. |
| High  | A patient with multi-system problems and multiple/significant complications (medical and/or social).  
|       | An unstable/deteriorating patient, with an uncommon presentation or without a clear diagnosis.  
|       | A critically-ill or injured patient who is unresponsive to first line treatment.  
|       | A patient presenting with a life threatening condition. |

Ref: [www.acem.org.au](http://www.acem.org.au)
Annex I. Clinical Supervisor Final Report

In my capacity as Clinical Supervisor, I am satisfied that …………………………………………………………….. (trainee’s name) from …………………………………………………………………………… (department, institution) has completed the National Collaborative Prescribing Programme Clinical Practicum successfully and is ready to sit for the summative assessments.

I understand that upon successful completion of the summative assessments, he/she will be awarded a Certificate of Successful Completion of the National Collaborative Prescribing Programme and is eligible to apply for collaborative prescribing privileges in my institution as stated in the Collaborative Practice Agreement.

Clinical Supervisor’s name: 

………………………………………………………………………………

Name stamp: 

………………………………………………………………………………

Signature: 

………………………………………………………………………………

Date: 

………………………………………………………………………………
### Annex J. Overview of Programme Structure (2nd cohort)

<table>
<thead>
<tr>
<th>Week</th>
<th>Teaching Sessions (APNs)</th>
<th>Teaching Sessions (Pharmacists)</th>
<th>Clinical Practicum</th>
<th>Assessments</th>
</tr>
</thead>
</table>
| 1    | Introduction and program overview  
      Principles of prescribing 1 | Overview of drug use in Singapore  
      History-taking | 80 hours involving the following allocation of time:  
      • 30 hours DIRECT supervision:  
      - 12 hours with named clinical supervisor  
      - 18 hours with Senior Resident and above | Presentation of drug monograph; Portfolio review 1 |
| 2    | Scope of practice and personal formulary  
      Summarising and presenting to assessor  
      History-taking | Basic ECG interpretation  
      History-taking |  
      • 10 hours INDIRECT supervision by above | |
| 3    | Principles of prescribing 2  
      ABG interpretation | Pharmacotherapy for special populations  
      Physical examination 1 |  
      • 10 hours INDIRECT supervision by peers  
      i.e. Resident/Medical Officer, APN or pharmacist  
      • 10 hours INDIRECT supervision by peers | Portfolio review 2 |
| 4    | Prescribing in a team context  
      Communication skills – SBAR phone calls | Pharmaco therapeutics  
      (Diabetes mellitus)  
      Physical examination 1 |  
      • 10 hours INDIRECT supervision by above  
      • 30 hours DIRECT supervision by peers i.e. Resident/Medical Officer, APN or pharmacist | Portfolio review 3 |
| 5    | Skin/dermatological conditions  
      Communication skills | Pharmacotherapy for infectious diseases  
      Physical examination 2 |  
      | Quiz (skin/dermatological conditions) |
| 6    | Communication skills  
      OSCE briefing | Pharmaco therapeutics  
      (Cardiovascular diseases)  
      Physical examination 2 |  
      | Formative OSCE |
| 7    | Pharmaco therapeutics  
      (Psychiatry, Neurology, Gastrointestinal & Renal diseases)  
      Physical examination 3 | Physical examination  
      – Revision 3  
      Communication skills  
      Mock OSCE I |  
      | |
| 8    | Interpreting diagnostic tests and procedures  
      Mock OSCE II |  
      | Portfolio review 4 |
| 9    | Obtaining history from special populations  
      Basic x-ray interpretation | Pharmaco therapeutics  
      (Thyroid disorders) |  
      | |
| 10   | Nil |  
      | Clinical Practicum must be completed by Week 10 |
| 11   | Nil |  
      | Final written exam; Portfolio review 4 |
| 12   | Nil |  
      | Summative OSCE |

*in red are clinical teaching sessions*